Study of GBT021601 in Participants With Renal Impairment - Trial NCT05878704
Access comprehensive clinical trial information for NCT05878704 through Pure Global AI's free database. This Phase 1 trial is sponsored by Pfizer and is currently Recruiting. The study focuses on Renal Impairment. Target enrollment is 56 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
NCT05878704
Phase 1
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT05878704
View on ClinicalTrials.gov
Study of GBT021601 in Participants With Renal Impairment
A Phase I, Open-Label, Single-Dose, Non-Randomized, Parallel Group Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of GBT021601, an Oral Hemoglobin S Polymerization Inhibitor, in Adult Participants With Renal Impairment
Study Focus
Sponsor & Location
Pfizer
Tustin,Miami, United States of America
Timeline & Enrollment
Phase 1
Jun 29, 2023
Jul 09, 2024
56 participants
Primary Outcome
Concentration of GBT021601 in whole blood and plasma,Single-dose PK parameters
Summary
Renal Impairment study of GBT021601.
ICD-10 Classifications
Renal failure
Disorders resulting from impaired renal tubular function
Disorder resulting from impaired renal tubular function, unspecified
Other disorders resulting from impaired renal tubular function
Acute renal failure
Data Source
ClinicalTrials.gov
NCT05878704
Non-Device Trial